|  |  |  | Univariate | Multivariate | ||
---|---|---|---|---|---|---|---|
Variables | n (%) | 3-year survival | 5-year survival | P-value | HR | 95% CI | P-value |
Male sex | 110 (79%) | 45.8% | 41.2% | 0.180 | Â | Â | Â |
Female sex | 29 (21%) | 56.6% | 40.4% | Â | Â | Â | Â |
Age (years) | |||||||
  ≤ 80 | 109 (78%) | 24.9% | 24.9% | 0.084 |  |  |  |
  > 80 | 30 (22%) | 52.4% | 45.2% |  |  |  |  |
BMI (kg/m2) | |||||||
  > 25 | 34 (25%) | 48.0% | 48.0% | 0.699 |  |  |  |
  ≤ 25 | 105 (75%) | 48.3% | 39.3% |  |  |  |  |
ALBI | |||||||
 grade III | 30 (22%) | 49.5% | 44.6% | 0.708 |  |  |  |
  < grade III | 109 (78%) | 47.7% | 40.1% |  |  |  |  |
HBV | |||||||
 (+) | 27 (19%) | 63.2% | 47.7% | 0.236 |  |  |  |
 (−) | 112 (81%) | 44.1% | 37.7% |  |  |  |  |
HCV | |||||||
 (+) | 70 (50%) | 40.8% | 38.6% | 0.163 |  |  |  |
 (−) | 69 (50%) | 56.4% | 44.2% |  |  |  |  |
DM | |||||||
 (+) | 29 (21%) | 57.5% | 43.6% | 0.674 |  |  |  |
 (−) | 110 (79%) | 45.2% | 39.9% |  |  |  |  |
NLR | |||||||
  ≥ 4 | 13 (9%) | 19.4% | 19.4% | 0.279 |  |  |  |
  < 4 | 126 (91%) | 49.9% | 42.5% |  |  |  |  |
PLT (×104/μL) | |||||||
 normal (13–35) | 97 (70%) | 50.4% | 42.4% | 0.595 |  |  |  |
 abnormal | 42 (30%) | 44.1% | 39.2% |  |  |  |  |
Hb (g/dL) | |||||||
 normal (13.5–15.8) | 95 (68%) | 50.5% | 41.6% | 0.795 |  |  |  |
 abnormal | 44 (32%) | 44.3% | 40.9% |  |  |  |  |
PT (%) | |||||||
 normal (70–130) | 125 (90%) | 50.5% | 42.5% | 0.125 |  |  |  |
 abnormal | 14 (10%) | 28.8% | 28.8% |  |  |  |  |
AST (U/L) | |||||||
 normal (13–33) | 71 (51%) | 45.6% | 33.9% | 0.888 |  |  |  |
 abnormal | 68 (49%) | 51.1% | 48.1% |  |  |  |  |
ALT (U/L) | |||||||
 normal (8–42) | 100 (72%) | 48.8% | 41.0% | 0.770 |  |  |  |
 abnormal | 39 (28%) | 46.8% | 40.9% |  |  |  |  |
CHE (g/dL) | |||||||
 normal (229–521) | 77 (55%) | 53.8% | 44.9% | 0.251 |  |  |  |
 abnormal | 62 (45%) | 41.7% | 36.4% |  |  |  |  |
Alb (g/dL) | |||||||
 normal (4.0–5.0) | 115 (83%) | 48.5% | 39.8% | 0.878 |  |  |  |
 abnormal | 24 (17%) | 46.7% | 46.7% |  |  |  |  |
T-chol (mg/dL) | |||||||
 normal (128–219) | 118 (85%) | 49.4% | 43.0% | 0.907 |  |  |  |
 abnormal | 20 (14%) | 42.1% | 31.6% |  |  |  |  |
PIVKA-II (mAU/mL) | |||||||
 normal (< 40) | 62 (45%) | 61.0% | 51.0% | 0.048 | 1.321 | 0.778–2.240 | 0.320 |
 abnormal | 77 (55%) | 37.7% | 33.0% |  |  |  |  |
AFP (ng/mL) | |||||||
 normal (> 10) | 68 (49%) | 58.8% | 48.9% | 0.036 | 1.612 | 0.960–2.707 | 0.071 |
 abnormal | 68 (49%) | 38.7% | 33.5% |  |  |  |  |
Tumor number | |||||||
 solitary | 113 (81%) | 51.8% | 44.5% | 0.025 | 1.810 | 1.025–3.197 | 0.041 |
 multiple | 26 (19%) | 31.4% | 18.8% |  |  |  |  |
Tumor size | |||||||
 3 cm < | 71 (51%) | 49.5% | 43.4% | 0.938 |  |  |  |
  ≤ 3 cm | 54 (39%) | 52.6% | 42.7% |  |  |  |  |
Poor differentiation | 20 (14%) | 42.1% | 28.1% | 0.337 | Â | Â | Â |
Others (well, moderately) | 119 (86%) | 49.3% | 43.6% | Â | Â | Â | Â |
IM | |||||||
 (+) | 19 (14%) | 5.6% | 5.6% | < 0.001 | 4.115 | 2.255–7.510 | < 0.001 |
 (−) | 120 (86%) | 56.1% | 47.5% |  |  |  |  |
Vp | |||||||
 (+) | 26 (19%) | 28.4% | 28.4% | 0.016 | 1.490 | 0.824–2.695 | 0.187 |
 (−) | 113 (81%) | 52.8% | 43.5% |  |  |  |  |
Low SMI | 86 (62%) | 46.1% | 39.8% | 0.335 | Â | Â | Â |
High SMI | 53 (38%) | 51.9% | 43.9% | Â | Â | Â | Â |
Blood transfusion | |||||||
 (+) | 22 (16%) | 24.6% | 24.6% | 0.008 | 2.288 | 1.244–4.207 | 0.008 |
 (−) | 117 (84%) | 52.4% | 44.4% |  |  |  |  |